^
    Back
    Association details:
    Biomarker:NPM1 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:decitabine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2019
    Title:

    DNMT3Awt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

    Excerpt:
    ...we retrospectively analyzed higher risk MDSs who accepted decitabine therapy...A remarkably prolonged median survival was also shown in patients harboring NPM1mut DNMT3Awt (median survival of 80M), which is significantly longer than that of patients without NPM1 mutation (18M) (p = 0.012)...
    DOI:
    10.1182/blood-2019-124008